Impact of charlson comorbidity index varies by age in patients with prostate cancer treated by radical prostatectomy: A competing risk regression analysis

Joo Yong Lee, Dae Hun Lee, Namhoon Cho, KoonHo Rha, Youngdeuk Choi, Sung Joon Hong, Seung Choul Yang, Kang Su Cho

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: To investigate the prognostic impact of the Charlson comorbidity index (CCI) on either cancer-specific mortality (CSM) or other-cause mortality (OCM) according to age in patients with prostate cancer (PC) who underwent radical prostatectomy (RP). Methods: Data from 336 patients who underwent RP for PC between 1992 and 2005 were analyzed. Variables, including the preoperative prostate-specific antigen (PSA), prostate volume, clinical stage, and pathologic stage, were compared across age groups (<65 or ≥65 years old). Preexisting comorbidities were evaluated by the CCI, and patients were classified into two CCI score categories (0 or ≥1). Results: The median (interquartile range) follow-up period was 96 (85-121) months. Subjects were divided into two subgroups according to age: <65 years (n = 151) or ≥65 years (n = 185). There was no significant difference in PSA, biopsy Gleason sum, body mass index, pathologic stage, or CCI between the two age groups. OCM was significantly associated with the CCI score (P = 0.011). Cumulative incidence estimates obtained from competing risk regression analysis indicated that CCI was not associated with CSM (P = 0.795) or OCM (P = 0.123) in the ≥65-year group. However, in men <65 years, cumulative incidence estimates for OCM were significantly associated with CCI (P = 0.036). Conclusions: CCI was independently associated with OCM after RP, but only in men <65 years old. CCI was not associated with CSM in either age group. Accordingly, a thorough evaluation of patient's comorbidities is mandatory when considering aggressive surgical treatment, especially in relatively young patients.

Original languageEnglish
Pages (from-to)677-683
Number of pages7
JournalAnnals of Surgical Oncology
Volume21
Issue number2
DOIs
Publication statusPublished - 2014 Feb 1

Fingerprint

Prostatectomy
Comorbidity
Prostatic Neoplasms
Regression Analysis
Mortality
Age Groups
Prostate-Specific Antigen
Neoplasms
Incidence
Prostate
Body Mass Index
Biopsy

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

@article{9a9472ba56d54d9f8e3a8779a980bb54,
title = "Impact of charlson comorbidity index varies by age in patients with prostate cancer treated by radical prostatectomy: A competing risk regression analysis",
abstract = "Purpose: To investigate the prognostic impact of the Charlson comorbidity index (CCI) on either cancer-specific mortality (CSM) or other-cause mortality (OCM) according to age in patients with prostate cancer (PC) who underwent radical prostatectomy (RP). Methods: Data from 336 patients who underwent RP for PC between 1992 and 2005 were analyzed. Variables, including the preoperative prostate-specific antigen (PSA), prostate volume, clinical stage, and pathologic stage, were compared across age groups (<65 or ≥65 years old). Preexisting comorbidities were evaluated by the CCI, and patients were classified into two CCI score categories (0 or ≥1). Results: The median (interquartile range) follow-up period was 96 (85-121) months. Subjects were divided into two subgroups according to age: <65 years (n = 151) or ≥65 years (n = 185). There was no significant difference in PSA, biopsy Gleason sum, body mass index, pathologic stage, or CCI between the two age groups. OCM was significantly associated with the CCI score (P = 0.011). Cumulative incidence estimates obtained from competing risk regression analysis indicated that CCI was not associated with CSM (P = 0.795) or OCM (P = 0.123) in the ≥65-year group. However, in men <65 years, cumulative incidence estimates for OCM were significantly associated with CCI (P = 0.036). Conclusions: CCI was independently associated with OCM after RP, but only in men <65 years old. CCI was not associated with CSM in either age group. Accordingly, a thorough evaluation of patient's comorbidities is mandatory when considering aggressive surgical treatment, especially in relatively young patients.",
author = "Lee, {Joo Yong} and Lee, {Dae Hun} and Namhoon Cho and KoonHo Rha and Youngdeuk Choi and Hong, {Sung Joon} and Yang, {Seung Choul} and Cho, {Kang Su}",
year = "2014",
month = "2",
day = "1",
doi = "10.1245/s10434-013-3326-6",
language = "English",
volume = "21",
pages = "677--683",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "2",

}

Impact of charlson comorbidity index varies by age in patients with prostate cancer treated by radical prostatectomy : A competing risk regression analysis. / Lee, Joo Yong; Lee, Dae Hun; Cho, Namhoon; Rha, KoonHo; Choi, Youngdeuk; Hong, Sung Joon; Yang, Seung Choul; Cho, Kang Su.

In: Annals of Surgical Oncology, Vol. 21, No. 2, 01.02.2014, p. 677-683.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Impact of charlson comorbidity index varies by age in patients with prostate cancer treated by radical prostatectomy

T2 - A competing risk regression analysis

AU - Lee, Joo Yong

AU - Lee, Dae Hun

AU - Cho, Namhoon

AU - Rha, KoonHo

AU - Choi, Youngdeuk

AU - Hong, Sung Joon

AU - Yang, Seung Choul

AU - Cho, Kang Su

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Purpose: To investigate the prognostic impact of the Charlson comorbidity index (CCI) on either cancer-specific mortality (CSM) or other-cause mortality (OCM) according to age in patients with prostate cancer (PC) who underwent radical prostatectomy (RP). Methods: Data from 336 patients who underwent RP for PC between 1992 and 2005 were analyzed. Variables, including the preoperative prostate-specific antigen (PSA), prostate volume, clinical stage, and pathologic stage, were compared across age groups (<65 or ≥65 years old). Preexisting comorbidities were evaluated by the CCI, and patients were classified into two CCI score categories (0 or ≥1). Results: The median (interquartile range) follow-up period was 96 (85-121) months. Subjects were divided into two subgroups according to age: <65 years (n = 151) or ≥65 years (n = 185). There was no significant difference in PSA, biopsy Gleason sum, body mass index, pathologic stage, or CCI between the two age groups. OCM was significantly associated with the CCI score (P = 0.011). Cumulative incidence estimates obtained from competing risk regression analysis indicated that CCI was not associated with CSM (P = 0.795) or OCM (P = 0.123) in the ≥65-year group. However, in men <65 years, cumulative incidence estimates for OCM were significantly associated with CCI (P = 0.036). Conclusions: CCI was independently associated with OCM after RP, but only in men <65 years old. CCI was not associated with CSM in either age group. Accordingly, a thorough evaluation of patient's comorbidities is mandatory when considering aggressive surgical treatment, especially in relatively young patients.

AB - Purpose: To investigate the prognostic impact of the Charlson comorbidity index (CCI) on either cancer-specific mortality (CSM) or other-cause mortality (OCM) according to age in patients with prostate cancer (PC) who underwent radical prostatectomy (RP). Methods: Data from 336 patients who underwent RP for PC between 1992 and 2005 were analyzed. Variables, including the preoperative prostate-specific antigen (PSA), prostate volume, clinical stage, and pathologic stage, were compared across age groups (<65 or ≥65 years old). Preexisting comorbidities were evaluated by the CCI, and patients were classified into two CCI score categories (0 or ≥1). Results: The median (interquartile range) follow-up period was 96 (85-121) months. Subjects were divided into two subgroups according to age: <65 years (n = 151) or ≥65 years (n = 185). There was no significant difference in PSA, biopsy Gleason sum, body mass index, pathologic stage, or CCI between the two age groups. OCM was significantly associated with the CCI score (P = 0.011). Cumulative incidence estimates obtained from competing risk regression analysis indicated that CCI was not associated with CSM (P = 0.795) or OCM (P = 0.123) in the ≥65-year group. However, in men <65 years, cumulative incidence estimates for OCM were significantly associated with CCI (P = 0.036). Conclusions: CCI was independently associated with OCM after RP, but only in men <65 years old. CCI was not associated with CSM in either age group. Accordingly, a thorough evaluation of patient's comorbidities is mandatory when considering aggressive surgical treatment, especially in relatively young patients.

UR - http://www.scopus.com/inward/record.url?scp=84896740199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896740199&partnerID=8YFLogxK

U2 - 10.1245/s10434-013-3326-6

DO - 10.1245/s10434-013-3326-6

M3 - Article

C2 - 24145996

AN - SCOPUS:84896740199

VL - 21

SP - 677

EP - 683

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 2

ER -